Patrick G. Enright, Director at Jazz Pharmaceuticals plc (JAZZ), sold 11,948 shares at $152.88 ($1.8M) on 2022-11-22, disclosed to the SEC on 2022-11-25.
Open-market sale of $1.8M JAZZ by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $149.18 | 2,905 | $433K | 24.2% |
| 2 | $149.18 | 2,905 | $433K | 24.2% |
| 3 | $149.90 | 2,069 | $310K | 17.3% |
| 4 | $149.90 | 2,069 | $310K | 17.3% |
| 5 | $152.88 | 2,000 | $306K | 17.1% |
| Total | $150.05 avg | 11,948 |
| $1.8M |
| 100% |
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.5M | — | Filing → |
| VERA | BUY | 2025-06-25 | $10.6M | — | Filing → |
| BIOA | BUY | 2024-09-27 | $7.2M | — | Filing → |